Life Extension® Announces Recruitment For Alzheimer's Clinical Trial In South Florida
The objective of Life Extension's new clinical trial is to measure the effects of weekly injections of Enbrel® (generic name etanercept), a commonly used medication for autoimmune disorders such as rheumatoid arthritis, and nutritional supplements that may help suppress the inflammatory factor implicated in the neuronal degeneration of Alzheimer's disease. Twenty million Americans today are destined to contract Alzheimer's disease, an affliction that robs memory, intelligence and eventually the most rudimentary cognitive abilities. The few medications currently approved to treat Alzheimer's symptoms produce only modest, short-term effects. Some patients cannot tolerate them at all.
Dr. Steven Hirsch, Director of Clinical Research at Life Extension, stated that "Up until now, a diagnosis of Alzheimer's disease meant one was destined to slowly be deprived of all cognitive function, a condition that tops the list of aging people's disease fears. This is the first clinical trial sponsored by Life Extension that will permit us to better understand Alzheimer's disease and how traditional medications, in conjunction with nutritional supplements, may affect its progress. We are seeking volunteers who meet the criteria for inclusion into the study in order to help future patients diagnosed with the disease."
Source: Life Extension
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Extension, Life. "Life Extension® Announces Recruitment For Alzheimer's Clinical Trial In South Florida." Medical News Today. MediLexicon, Intl., 27 Aug. 2011. Web.
30 May. 2017. <http://www.medicalnewstoday.com/releases/233450.php>
Extension, L. (2011, August 27). "Life Extension® Announces Recruitment For Alzheimer's Clinical Trial In South Florida." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.